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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The impact of the introduction of newer anti-diabetic agents on the
treatment pattern in the booming diabetic population remains unclear. We examined the
patterns and temporal trends of anti-diabetic drug use in Taiwan, with particular emphasis
on combination therapy.
Methods: We searched the Taiwan National Health Insurance Database during 2000e2009 to
identify outpatient prescriptions of anti-diabetic drugs, including human insulins and insulin
analogues, sulfonylureas, glinides, metformin, thiazolidinediones, alpha-glucosidase inhibi-
tors, and dipeptidyl peptidase-4 inhibitors. Glucose-lowering treatments were classified ac-
cording to pattern (oral agents only, insulins only, and oral agents and insulins combined)
and a number of different classes of anti-diabetic drugs. Insulin therapy and combination
therapy with two oral anti-diabetic drugs (OAD) were further classified according to individual
drug combination patterns.
Results: Although metformin remained the mainstay of anti-diabetic treatment, patients
receiving combination therapy of oral glucose-lowering agents, either with or without insulin,
significantly increased, from approximately 40% in 2000 to 60% in 2009, particularly in relation
to the newer agents, including glinides, alpha-glucosidase inhibitors, and long-acting insulin
analogues. Use of sulfonylureas and thiazolidinediones decreased substantially. For insulin
therapy, the most commonly prescribed drugs were premix insulin analogues and basal insulin
analogues, accounting for one-third of total insulin prescriptions in 2009.of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan.
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2.09.009
618 C.-H. Chang et al.Conclusion: We found an increasing complexity of anti-diabetic therapy during the past
decade in Taiwan. Further studies are needed to evaluate whether this treatment pattern will
lead to improved clinical outcomes in terms of cost-effectiveness.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Type 2 diabetes has continued to be an important public
health crisis, despite increased public awareness, intensive
monitoring, and aggressive management. It is estimated that
more than 366 million people worldwide have diabetes, and
this may increase to over 552million by 2030.1,2 In the United
States, more than 20 million individuals have diabetes, and
this number is projected to increase 165%by2050, accounting
for one-third of the population.3,4 Type 2 diabetes has also
become an important challenge in Asia, including Taiwan.5 In
a recently-published study analyzing the National Health
Insurance claims database, an universal increase in the
prevalence of type 2 diabetes was found for both men and
women, with the highest growth among those aged <40 and
>80 from 1999 to 2004.6 There was a 31% increase in the
incidence of type 2 diabetes for men and a 4.3% increase for
women in the <40 years’ old age group, despite the modest
decrease in incidence for men and women of age 40. The
tremendous increases in the numbers of patients with dia-
betes represent a huge economic burden to our society.7
There has also been an increasing complexity of medical
treatments for diabetes, mostly due to the availability of
new drugs and therapeutic classes.8 Following the decades-
long use of metformin and sulfonylureas, four additional
classes of oral anti-diabetic drugs (OAD) have come into the
market: these comprise alpha-glucosidase inhibitors, thia-
zolidinediones, the non-sulfonylurea insulin secretagogues
glinides, and dipeptidyl peptidease-4 inhibitors. Meanwhile,
rapid-acting insulin analogues and long-acting insulin
analogues have also become widely used due to their
improved pharmacokinetic and pharmacodynamic proper-
ties. These anti-diabetic drugs act on different pharmaco-
logical mechanisms and have completely different safety
profiles, although clinical trials suggest that they have
comparable efficacy in terms of their overall glucose
lowering effect.9 Evidence has suggested that some of these
newer drugs may either be superior in terms of durability of
glycemic control or have potential cardiovascular or cere-
brovascular protective effects.10e13 As a result, physicians
have tended to prescribe a combination therapy of anti-
diabetic agents for a balanced correction of the underlying
metabolic derangements associated with type 2 diabetes
and to avoid the adverse reaction associated with high-dose
anti-diabetic agent treatment.14 Although most therapeutic
guidelines suggest metformin as the initial treatment for
type 2 diabetes, no clear recommendation has been made
for the second-line and subsequent treatment strategies of
these newer agents.15 The impact of the introduction of
these newer agents to the market on the treatment pattern
in the booming diabetic population remains unclear.
Although several studies have described changes in anti-
diabetic therapy over the past decade, few have focused
on the trends in utilization of combination therapy.16e26Therefore, we examined the patterns and temporal trends
of anti-diabetic drugs use, with particular emphasis on
combination therapy.
Methods
A single-payer and compulsory National Health Insurance
program was implemented in Taiwan in 1995. The Taiwan
National Health Insurance claims database includes data on
complete outpatient visits, hospital admissions, prescrip-
tions, disease and vital status for 99% of the Taiwanese
population of 23 million people. We established the longi-
tudinal medical history of each beneficiary by linking
several computerized administrative and claims datasets,
and the National Death Registry and Cancer Registry
through the civil identification number unique to each
beneficiary, in addition to their date of birth. The protocol
of this study was approved by the National Taiwan Univer-
sity Hospital Research Ethics Committee.
We searched the Taiwan National Health Insurance
Database for the source population during 2000e2009 to
identify any hospitalized event with diabetes as one of the
discharge diagnoses (The International Classification of
Diseases, 9th Revision, Clinical Modification, ICD-9-CM code
250) and used outpatient claims to find any visit for dia-
betes (ICD-9-CM code 250 and A code A181). Data from
a random sample of one-third of the total number of
patients with any diabetes diagnostic codes in the claims
database were retrieved. Patients were classified as having
diabetes mellitus and included in the analysis if they either
had at least one hospital admission with a diagnostic code
of diabetes or had three or more outpatient visits with
a diabetes diagnostic code in each calendar year.
We identified patients who had ever received outpatient
prescriptions of anti-diabetic drugs, including human insulins
and insulin analogues, sulfonylureas, glinides, metformin,
thiazolidinediones (TZD), alpha-glucosidase inhibitors, and
dipeptidyl peptidase-4 (DPP4) inhibitors (anatomical thera-
peutic chemical classification system codes are provided in
a Supplementary Table). Our unit of observation was anti-
diabetic prescription, which may include more than one
anti-diabetic drug. Glucose-lowering treatments were clas-
sified according to pattern (oral agents only, insulins only,
oral agents and insulins combined) and number of different
classes of anti-diabetic drugs. Insulin therapy and two-OAD
combination therapy were further classified according to
individual drug combination patterns.
Statistical analysis
We calculated the proportion of prescriptions belonging to
a particular anti-diabetic therapy category each year to
examine the time trend. The mean number of prescriptions
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Anti-diabetic treatment in Taiwan 619for the diabetic patients was also calculated with the use of
the estimated total number of diabetes patients in Taiwan.
Results
As the prevalence of diabetes mellitus increased in Taiwan,
the total number of anti-diabetic prescriptions increased
significantly from 4,605,213 in 2000, to 9,548,583 in 2009,
with the mean number of prescriptions per person
increasing from 6.5 in 2000 to 7.8 in 2009 (Table 1). OAD
only therapy made up approximately 90% of the prescrip-
tions in 2000; this decreased slightly to 87.5% in 2009. While
6% of prescriptions were insulin-only therapy, there was
a significantly increasing trend for insulin and OAD combi-
nation therapy, with the proportion rising from 3.33% in
2000 to 6.49% in 2009. Meanwhile, the proportion of
combination therapy with different classes of anti-diabetic
agents also increased substantially.
For OAD monotherapy, metformin was the most
commonly used medication, with the proportion of
prescriptions remaining at 50e60% during the study period
(Table 2). In contrast, the proportion of sulfonylurea mon-
otherapy decreased from 40% in 2000 to 30% in 2009. Use of
glinides and alpha-glucosidase inhibitors rose significantly,
although alpha-glucosidase inhibitors reached a plateau in
2006. Notably, the proportion of TZD monotherapy
increased after it became available in Taiwan’s market in
2001, reaching 2.28% in 2004, but decreased to less than 1%
in 2009 (Table 2).
For two-OAD combination therapy, more than 90% were
metformin-based regimens. While metformin-based and
sulfonylurea-based therapy decreased significantly, falling
from 99% to 90% and 78%, respectively, during the study
period, glinides-based and alpha-glucosidase inhibitors-
based combination therapy increased substantially
(accounting for 14% and 11% of the total number of two-
OAD prescriptions in 2009), although alpha-glucosidase
inhibitor-based treatment seemed to reach a plateau
(Table 3). TZD combination therapy accounted for 10% of
the total number of two-OAD prescriptions in 2004 and then
decreased to 4% in 2009. For individual two-OAD regimens
in 2009, metformin plus sulfonylurea was the most common
prescription (70%), followed by metformin plus glinides
(10%), metformin plus alpha-glucosidase inhibitors (5%),
and sulfonylurea plus alpha-glucosidase inhibitors (4%).
For insulin therapy, the most commonly prescribed drug
was premix insulin, rising from 27% of total insulin
prescriptions in 2000 to 51% in 2006, and then slightly
decreasing to 47% in 2009. Premix insulin analogues became
available in 2004 and rapidly increased to 36% in 2009.
Similarly, the use of basal insulin analogues rose and
accounted for 33% of total insulin prescriptions in 2009,
mostly combined with OAD use. In contrast, the use of NPH
insulin and a short-acting insulin only regimen decreased
substantially during the study period (Table 4).
Discussion
The present study found that anti-diabetic therapy has
become increasingly complex during the past decade in
Taiwan. Although metformin has remained the mainstay of
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620 C.-H. Chang et al.anti-diabetic treatment, patients receiving combination
therapy of OADs with or without insulin significantly
increased from approximately 40% in 2000 to 60% in 2009,
particularly with the advent of newer agents including gli-
nides, alpha-glucosidase inhibitors, and long-acting insulin
analogues. This number was higher than that in the US (53%)
and Italy (50%), but lower than that of Canada (69%).23,25,26
In regard to OAD treatment patterns, we found that the
proportion of metformin use in Taiwan (58.5% of mono-
therapy and 90.2% of two-OAD combination) was substan-
tially higher than was that in the US, Canada, and Italy
(ranging from 46.7% to 66.5%).23,25,26 In contrast to the rela-
tively unchanged rate of metformin use during the past
decade, the use of sulfonylureas, including both mono-
therapy and combination therapy, significantly decreased by
between 20% and 25%. Similar trends of decreasing
prescription rates of sulfonylureas were also observed in
other countries. Notably, uses of glinides and alpha-
glucosidase inhibitors were significantly higher than in
Western countries. The proportion of prescriptions involving
glinideswas as high as 7% ofmonotherapy and14%of two-OAD
combination therapy, whereas glinides were used in only 2%
and7.6% of prescriptions in theUSand Italy, respectively.23,26
Similarly, alpha-glucosidase inhibitors were involved in 3% of
monotherapy and 10% of two-OAD combination therapy in
Taiwan and were used in less than 1% of prescriptions in the
US and Canada.23,25 Conversely, TZD was less commonly used
(0.6% of monotherapy and 4% of two-OAD combination
therapy in Taiwan, compared with a total of 5.7% in Italy,
12.9% in Canada, and 28% in the US).23,25,26
There was also a huge difference in insulin utilization
between Taiwan and other countries. The overall insulin use
(mono- and combination therapy) comprised about 12% of
the total prescriptions, which was similar to that in Canada
but lower than that in the US (28%) and Italy (22%).23,25,26
While the proportion of prescriptions of insulin only
therapy remained around 6% in Taiwan, the percentage of
combination therapy of insulin and oral agents significantly
increased from 3.3% in 2000 to 6.5% in 2009. Among all
insulin preparations, premixed insulins with insulin
analogues and long-acting insulin analogues each made up
about one-third of all insulin prescriptions in 2009. There
was a decreasing trend in the use of regular insulin and NPH
insulin both in Taiwan and in other countries.
As increasingly complex and costly therapies are being
applied to an increasing diabetic population, the above
prescription patterns have a direct and substantial impact on
health care expenditure, for both patients and third-party
payers. One earlier study that analyzed data from a national
sample ofmore than half of the retail pharmacies available in
the US in 2001e2007 found that increasing use of TZD, newer
insulins, sitagliptin, and exenatide were largely responsible
for the recent rise in drug expenditures. 23 Furthermore,
a recently published study using data fromapharmacybenefit
manager withmore than 50million beneficiaries across the US
suggested that, among newly diagnosed diabetic patients,
higher drug costs over a 6-month period were largely attrib-
uted to the initial medication choices, with the greatest
expense being involved for those started on new drugs, such
as alpha-glucosidase inhibitors, TZD, glinides, and DPP4-
inhibitors.27 Although the study authors suggested that
putting all patients on metformin and sulfonylurea as the
Table 3 Proportion of prescriptions of two oral anti-diabetic drugs combination therapy in 2000e2009 in Taiwan.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Number of prescriptions 1,562,478 1,895,280 2,168,805 2,294,409 2,691,204 2,931,429 3,159,714 3,410,397 3,627,672 3,728,157
Metformin þ sulfonylurea 98.69 93.07 83.82 77.25 73.41 73.68 73.11 72.49 71.97 70.19
Metformin þ glinides 0.09 2.57 4.89 5.95 6.91 6.88 7.64 8.62 10.11 10.16
Metformin þ TZDs d 0.97 4.27 5.56 6.08 5.71 5.28 4.29 3.30 2.70
Metformin þ a-glucosidase
inhibitors
0.87 1.74 2.12 3.06 3.37 4.00 4.25 4.48 5.10 5.14
Metformin þ DPP4-inhibitors d d d d d d d d d 1.96
Sulfonylurea þ glinides 0.01 0.07 0.35 1.02 1.42 1.29 1.52 2.07 2.24 2.33
Sulfonylurea þ TZDs 0.62 2.35 2.96 3.34 2.72 2.18 1.72 1.09 0.82
Sulfonylurea þ a-glucosidase
inhibitors
0.35 0.78 1.47 2.72 3.52 3.76 3.96 4.22 4.21 3.92
Sulfonylurea þ DPP4-inhibitors d d d d d d d d 0.63
Glinides þ TZDs 0.07 0.30 0.48 0.53 0.43 0.43 0.37 0.28 0.22
Glinides þ a-glucosidase
inhibitors
<0.01 0.07 0.25 0.67 0.98 1.10 1.25 1.44 1.50 1.44
Glinides þ DPP4-inhibitors d d d d d d d d d 0.23
TZDs þ a-glucosidase inhibitors 0.03 0.18 0.32 0.45 0.43 0.38 0.30 0.19 0.14
TZDs þ DPP4-inhibitors d d d d d d d d d 0.01
a-glucosidase inhibitors þ
DPP4-inhibitors
d d d d d d d d d 0.11
Metformin þ others 99.65 98.35 95.10 91.82 89.77 90.27 90.28 89.88 90.48 90.15
Sulfonylurea þ others 99.05 94.54 87.99 83.95 81.69 81.45 80.77 80.50 79.51 77.89
Glinides þ others 0.10 2.78 5.79 8.12 9.84 9.70 10.84 12.50 14.13 14.38
TZDs þ others 1.69 7.10 9.32 10.40 9.29 8.27 6.68 4.86 3.89
a-glucosidase inhibitors þ others 1.22 2.62 4.02 6.77 8.32 9.29 9.84 10.44 11.00 10.75
DPP4-inhibitors þ others d d d d d d d d d 2.94
TZD Z thiazolidinediones.
DPP4 Z Dipeptidyl peptidase-4.
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Table 4 Proportion of prescriptions of insulin therapy in 2000e2009 in Taiwan.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Number of prescriptions 484,938 531,429 576,030 590,370 697,548 755,607 837,066 957,342 1,091,166 1,197,669
Premix insulin 27.05 32.61 33.99 37.75 42.56 48.78 51.34 50.33 48.49 46.57
Insulin analogues d d d d 4.91 16.64 24.61 27.86 32.39 35.92
Alone d d d d 3.28 10.74 15.43 17.14 19.68 21.13
With OAD d d d d 1.50 5.43 8.52 10.18 12.17 13.82
With other insulins d d d d 0.13 0.47 0.66 0.54 0.54 0.97
Human insulins 27.05 32.61 33.99 37.75 37.65 32.14 26.73 22.47 16.10 10.65
Alone 18.43 21.75 22.23 23.95 23.43 20.49 17.10 14.13 10.08 6.70
With OAD 7.72 9.97 11.26 13.31 13.81 11.31 9.30 8.10 5.87 3.77
With other insulins 0.90 0.89 0.50 0.49 0.41 0.34 0.33 0.24 0.15 0.18
Basal insulins 53.58 45.82 43.77 43.91 47.16 41.65 40.57 43.14 46.25 48.42
Long-acting analogues d d d d 4.39 4.07 8.58 17.66 26.71 32.96
Alone d d d d 0.46 0.43 0.96 1.88 2.76 3.10
With OAD d d d d 2.56 2.37 5.43 12.65 20.11 24.65
With other insulins d d d d 1.37 1.27 2.19 3.13 3.84 5.21
NPH 53.58 45.82 43.77 43.91 42.77 37.58 31.99 25.48 19.54 15.46
Alone 18.35 14.19 12.46 11.21 10.58 9.09 7.56 5.78 4.21 3.13
With OAD 16.28 15.21 16.00 17.48 17.83 15.76 14.00 11.28 8.48 4.76
With other insulins 18.95 16.42 15.31 15.22 14.36 12.73 10.43 8.42 6.85 7.57
Short-acting insulin only 19.37 21.58 22.24 18.34 10.26 9.59 8.08 6.53 5.28 5.02
Short-acting analogues d d d d 0.35 1.26 1.33 0.89 0.66 0.78
Alone d d d d 0.26 0.94 0.99 0.66 0.54 0.61
With OAD d d d d 0.06 0.26 0.32 0.23 0.12 0.16
Regular insulins 19.37 21.58 22.24 18.34 9.91 8.33 6.75 5.64 4.62 4.24
Alone 11.76 12.10 12.92 10.91 5.64 4.79 4.21 3.74 3.14 2.98
With OAD 7.61 9.48 9.32 7.43 4.27 3.54 2.54 1.90 1.48 1.26
OAD Z oral anti-diabetic agents.
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Anti-diabetic treatment in Taiwan 623initial treatment represented an opportunity for payers and
policy makers to mitigate drug costs, this policy may not
necessarily lead to a better clinical outcome or improved
quality of care. Since individual patients differed in terms of
age, diabetic duration, blood glucose level and risk of hypo-
glycemia, bodyweight, other cardiovascular risk profiles, life-
style factors, and medication adherence, a personalized
approach may be more appropriate than the so-called “one
size fits all” approach. Furthermore, concerns have been
raised that a health insurance coverage policy solely based on
cost containment may actually impair clinically rational and
equitable access to pharmacotherapeutic innovation.19 As
increasing evidence suggests that newer anti-diabetic agents
may have additional effects other than glucose lowering, and
many clinical trials targeted on cardiovascular endpoints are
ongoing, we suggest that more research into the comparative
effectiveness of clinical and economic outcomes is needed to
help in developing clinical practice guidelines and a drug
reimbursement policy on anti-diabetic therapy.
There are several limitations to this study. First, due to
government regulations, we analyzed data from a random
sample of one-third of patients instead of the total number
of patients with any diabetes diagnostic codes in the claims
database. However, this can still be regarded as a valid
sample for nationwide representativeness. Second, we
could not exclude the possibility that some diabetic
patients may pay out-of-pocket for glucose-lowering
medications that were not recorded in this nationwide
database. However, this may only comprise a very small
proportion because most of the anti-diabetic drugs are
costly, especially for long treatment duration. Finally, the
cost of DPP-4 inhibitors has been reimbursed by the
National Health Insurance since 2009. Although prescription
of sitagliptin, a DPP-4 inhibitor released in the US in
October 2006, rapidly increased to 10% of treatment visits 1
year later, we could not evaluate the utilization of this drug
class due to lack of data after 2009.
In conclusion, in this study we found an increasing
complexity of anti-diabetic therapy during the past decade
in Taiwan. The number of patients receiving combination
therapy of OAD, either with or without insulin, significantly
increased, particularly in relation to the inclusion of gli-
nides, alpha-glucosidase inhibitors, and new insulin
analogues. Further studies are needed to evaluate whether
this treatment pattern will lead to improved clinical
outcome in terms of cost-effectiveness.Acknowledgments
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